La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease.

Identifieur interne : 002721 ( Main/Merge ); précédent : 002720; suivant : 002722

Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease.

Auteurs : Joseph Flores [Canada] ; Ivan L. Cepeda ; Michael L. Cornfeldt ; John R. O'Kusky ; Doris J. Doudet

Source :

RBID : pubmed:17620984

English descriptors

Abstract

Previous studies have demonstrated that the intrastriatal implantation of human retinal pigment epithelial cells attached to gelatin microcarriers (hRPE-GM) ameliorates behavioral deficits in animal models of Parkinson disease. However, there are only sparse data on cell survival in the host. In this study, we characterized a variety of retinal pigment epithelial (RPE)-specific markers in vitro and used these markers to investigate the long-term survival of hRPE-GM implants. Sprague-Dawley rats (n = 22) were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and implanted with hRPE-GM without immunosuppression. Rats were euthanized at 48 hours, 7 days, 4 weeks, and 5 months postimplant and immunohistochemically processed using the following antibodies: 1) human-specific nuclear mitotic apparatus protein (NuMA-Ab2), 2) epithelial-specific extracellular matrix metalloproteinase inducer (EMMPRIN), 3) RPE cell-specific RPE65, and the inflammation markers 4) glial fibrillary acidic protein and 5) ED1 (rat CD68). Our analysis revealed NuMA-, EMMPRIN-, and RPE65-immunoreactive cells at different times postimplant. The morphologic features of hRPE cell implants (at 48 hours and 5 months) were confirmed by electron microscopy. Furthermore, despite evidence of chronic inflammation at the later time point, there is an appreciable number of surviving hRPE cells. This study suggests that hRPE-GM implants can survive in the absence of immunosuppression and can be potentially used as an alternative for treating Parkinson disease.

DOI: 10.1097/nen.0b013e318093e53a
PubMed: 17620984

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:17620984

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease.</title>
<author>
<name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada. joflores@interchange.ubc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L" last="Cepeda">Ivan L. Cepeda</name>
</author>
<author>
<name sortKey="Cornfeldt, Michael L" sort="Cornfeldt, Michael L" uniqKey="Cornfeldt M" first="Michael L" last="Cornfeldt">Michael L. Cornfeldt</name>
</author>
<author>
<name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R" last="O'Kusky">John R. O'Kusky</name>
</author>
<author>
<name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J" last="Doudet">Doris J. Doudet</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17620984</idno>
<idno type="pmid">17620984</idno>
<idno type="doi">10.1097/nen.0b013e318093e53a</idno>
<idno type="wicri:Area/PubMed/Corpus">001059</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001059</idno>
<idno type="wicri:Area/PubMed/Curation">001059</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001059</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001059</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001059</idno>
<idno type="wicri:Area/Ncbi/Merge">000788</idno>
<idno type="wicri:Area/Ncbi/Curation">000788</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000788</idno>
<idno type="wicri:doubleKey">0022-3069:2007:Flores J:characterization:and:survival</idno>
<idno type="wicri:Area/Main/Merge">002721</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease.</title>
<author>
<name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC, Canada. joflores@interchange.ubc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine/Neurology and the Pacific Parkinson's Research Centre, University of British Columbia, 2221 Wesbrook Mall, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L" last="Cepeda">Ivan L. Cepeda</name>
</author>
<author>
<name sortKey="Cornfeldt, Michael L" sort="Cornfeldt, Michael L" uniqKey="Cornfeldt M" first="Michael L" last="Cornfeldt">Michael L. Cornfeldt</name>
</author>
<author>
<name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R" last="O'Kusky">John R. O'Kusky</name>
</author>
<author>
<name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J" last="Doudet">Doris J. Doudet</name>
</author>
</analytic>
<series>
<title level="j">Journal of neuropathology and experimental neurology</title>
<idno type="ISSN">0022-3069</idno>
<imprint>
<date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Cell Survival</term>
<term>Cell Transplantation (methods)</term>
<term>Corpus Striatum (pathology)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Corpus Striatum (surgery)</term>
<term>Disease Models, Animal</term>
<term>Gelatin (therapeutic use)</term>
<term>Humans</term>
<term>Male</term>
<term>Microscopy, Electron, Transmission (methods)</term>
<term>Microspheres</term>
<term>Nerve Tissue Proteins (metabolism)</term>
<term>Parkinson Disease (etiology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (surgery)</term>
<term>Pigment Epithelium of Eye (physiology)</term>
<term>Pigment Epithelium of Eye (transplantation)</term>
<term>Pigment Epithelium of Eye (ultrastructure)</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Time Factors</term>
<term>Transplantation, Heterologous (methods)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Gelatin</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Cell Transplantation</term>
<term>Microscopy, Electron, Transmission</term>
<term>Transplantation, Heterologous</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Corpus Striatum</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Pigment Epithelium of Eye</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="transplantation" xml:lang="en">
<term>Pigment Epithelium of Eye</term>
</keywords>
<keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en">
<term>Pigment Epithelium of Eye</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cell Survival</term>
<term>Disease Models, Animal</term>
<term>Humans</term>
<term>Male</term>
<term>Microspheres</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Previous studies have demonstrated that the intrastriatal implantation of human retinal pigment epithelial cells attached to gelatin microcarriers (hRPE-GM) ameliorates behavioral deficits in animal models of Parkinson disease. However, there are only sparse data on cell survival in the host. In this study, we characterized a variety of retinal pigment epithelial (RPE)-specific markers in vitro and used these markers to investigate the long-term survival of hRPE-GM implants. Sprague-Dawley rats (n = 22) were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and implanted with hRPE-GM without immunosuppression. Rats were euthanized at 48 hours, 7 days, 4 weeks, and 5 months postimplant and immunohistochemically processed using the following antibodies: 1) human-specific nuclear mitotic apparatus protein (NuMA-Ab2), 2) epithelial-specific extracellular matrix metalloproteinase inducer (EMMPRIN), 3) RPE cell-specific RPE65, and the inflammation markers 4) glial fibrillary acidic protein and 5) ED1 (rat CD68). Our analysis revealed NuMA-, EMMPRIN-, and RPE65-immunoreactive cells at different times postimplant. The morphologic features of hRPE cell implants (at 48 hours and 5 months) were confirmed by electron microscopy. Furthermore, despite evidence of chronic inflammation at the later time point, there is an appreciable number of surviving hRPE cells. This study suggests that hRPE-GM implants can survive in the absence of immunosuppression and can be potentially used as an alternative for treating Parkinson disease.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002721 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002721 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:17620984
   |texte=   Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of Parkinson disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:17620984" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022